

Supplemental Table S1

	Stage 0 (without cortical fracture)	Stage 1 (with cortical fracture)
Active arthropathy (acute stage)	Mild inflammation / soft tissue oedema No skeletal deformity X-ray normal MRI abnormal (bone marrow edema, bone bruise, microfractures)	Severe inflammation / soft tissue edema Severe skeletal deformity X-ray abnormal (macrofractures) MRI abnormal (bone marrow oedema, bone bruise, macrofractures)
Inactive arthropathy	No inflammation No skeletal deformity X-ray normal MRI without significant bone marrow edema	No inflammation Severe skeletal deformity X-ray abnormal (past macrofractures) MRI without significant bone marrow edema

Table Legend:

The CF stage classification proposed by Chantelau and Grützner [17].

Supplemental Table S2

	N patients	Recurrence within category	Recurrence in others	Hazard Ratio	p value	HR, multivariate model *
Age 18-59 years	83/174 (48%)	30 (36%)	20 (22%)	1.77 (1.00-3.11)	0.049	1.36 (0.71-2.59, $p=0.35$ )
Male sex	109/174 (63%)	29 (27%)	21 (32%)	0.84 (0.48-1.48)	0.55	
Type 1 DM	63/174 (36%)	19 (30%)	31 (28%)	0.93 (0.52-1.64)	0.80	
Hypertension	135/172 (78%)	37 (27%)	12 (32%)	0.77 (0.40-1.49)	0.44	
Ischemic heart disease	23/174 (13%)	3 (13%)	47 (31%)	0.36 (0.11-1.17)	0.09	0.43 (0.13-1.43, $p=0.17$ )
eGFR < 60 ml/min/1.73 m <sup>2</sup>	71/172 (41%)	19 (27%)	30 (30%)	0.90 (0.50-1.59)	0.71	
HbA1c > 70 mmol/mol	61/164 (37%)	24 (39%)	21 (20%)	2.13 (1.19-3.84)	0.01	2.16 (1.17-4.00, $p=0.01$ )
Previous DFU	82/174 (47%)	18 (22%)	32 (35%)	0.59 (0.33-1.04)	0.07	0.55 (0.30-1.01, $p=0.06$ )
PAD	29/174 (17%)	7 (24%)	43 (30%)	0.81 (0.36-1.79)	0.60	
Osteoporosis	6/174 (3.4%)	0	50 (30%)	0.05 (0.01-24)	0.34	
Dialysis	8/174 (4.6%)	2 (25%)	48 (29%)	0.92 (0.23-3.84)	0.92	
Kidney transplant	10/174 (5.7%)	1 (10%)	50 (30%)	0.28 (0.04-2.01)	0.20	
CF stage 1 <sup>†</sup>	116/187 (62%)	36 (31%)	17 (24%)	1.34 (0.76-2.39)	0.31	

Table Legend:

Acute recurrence after uncasting (occurring < 1 year after introduction of definitive therapeutic footwear or discharge), divided according to different baseline characteristics and CF stage.

\*  $\chi^2$  15.1,  $p < 0.01$ .

† Includes first occurring contralateral CF events in the univariable analysis.

Supplemental Table S3

	N patients	Recurrence within category	Recurrence in others	Hazard Ratio	<i>p</i> value	HR, multivariate model *
Age 18-59 years	86/183 (47%)	7 (8.1%)	6 (6.1%)	1.23 (0.41-3.67)	0.71	
Male sex	114/183 (62%)	8 (7.0%)	5 (7.2%)	1.06 (0.35-3.24)	0.92	
Type 1 DM	67/183 (37%)	6 (8.9%)	7 (6.0%)	0.84 (0.28-2.52)	0.75	
Hypertension	142/181 (79%)	11 (7.7%)	2 (5.1%)	1.49 (0.33-6.73)	0.60	
Ischemic heart disease	23/183 (13%)	0	13 (8.1%)	0.04 (0.01-73)	0.40	
eGFR < 60 ml/min/1.73 m <sup>2</sup>	76/181 (42%)	6 (7.9%)	7 (6.7%)	1.56 (0.52-4.67)	0.43	
HbA1c > 70 mmol/mol	66/173 (38%)	2 (3.0%)	11 (10.2%)	0.29 (0.07-1.32)	0.11	
Previous DFU	88/183 (48%)	4 (4.5%)	9 (9.4%)	0.57 (0.18-1.85)	0.35	
PAD	32/183 (17%)	2 (6.2%)	11 (7.3%)	0.94 (0.21-4.27)	0.94	
Osteoporosis	6/183 (3.2%)	1 (17%)	4 (6.7%)	3.56 (0.46-28)	0.23	
Dialysis	9/183 (4.9%)	1 (11%)	12 (7.3%)	1.89 (0.25-15)	0.54	
Kidney transplant	10/183 (5.5%)	3 (30%)	10 (5.8%)	6.17 (1.69-22)	0.006	5.95 (1.63-22, <i>p</i> =0.007)
CF stage 1 <sup>†</sup>	124/197 (63%)	12 (9.7%)	2 (2.7%)	4.36 (0.97-20)	0.05	8.36 (1.08-64, <i>p</i> =0.04)

## Table Legend:

Ipsilateral recurrence regarded as new CF events (occurring ≥ 1 year after introduced definitive therapeutic footwear or discharge), divided according to different baseline characteristics and CF stage.

\*  $\chi^2$  15.6, *p* < 0.001

† Includes first occurring contralateral CF events in the univariable analysis.